Levitra An Amazing Apparition

Bayer and GlaxoSmithKline are the manufacturers allowed to produce this drug that got its approval from FDA (Food and Drug Administration) on 19th august 2003. Due to its increasingly productive results it has captured the market within a very short span of time.

The development of Levitra was initiated to challenge the monopoly of Viagra. For many years there was just only one drug that can solve sexual dysfunction, it was Viagra. A huge amount of money was made with this drug. Imagine, before Viagra, there were no drugs that could face sexual dysfunction, it is said that some foods or some plants were able to do the work, but nothing sure.

The corporation who developed Levitra was Bayer Pharmaceuticals. If Vardenafil HCl (Levitra) wanted to be a significant competition it would have to add some advantages that Viagra didn’t have. The primary advantage Levitra has over Viaga is that men take Levitra without regard to meals, making it more convenient to use.

Levitra is the second erectile dysfunctional drug to be approved by FDA. Cialis was the third. But it is expected that other drugs are going to make an apparition, and will work with a totally different mechanism. This fourth one may actually help female sexual dysfunction.

But another positive thing about Levitra is that it works so much faster than Viagra; and men who Buy Levitra don’t have to be with their stomach empty, Levitra is even faster on a full stomach. But the question is why Viagra is still more popular? In a first moment, most men with dysfunctional problems, Buy Viagra, that’s why and it’s very positioned in the mind of the consumers with dysfunctional problems.

Article Source: http://www.marketingarticlebank.com

Impotence Specialists is UK most trusted source for impotence treatment. Their website is visited by thousands of people with impotence problems worldwide. Check the following links for information about impotence treatment:
Cialis
Buy Levitra

Please Rate this Article

5 out of 54 out of 53 out of 52 out of 51 out of 5 

Not yet Rated